Viewing nowCombinationOlmeduo Tablet 10/40 mg
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.

MFDS item code 201404597 · Approved 2014.10.06 · Insurance code 670607120
Treatment of essential hypertension not controlled with monotherapy
This medication is used for the treatment of patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil. It effectively lowers blood pressure and helps prevent cardiovascular complications, thereby contributing to the overall improvement of the patient's health.
Administer 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Do not administer to the following patients under Precautions for Use.) ∘Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
The safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm or death to the fetus and newborn during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with allergies to the active ingredients or similar compounds, pregnant or nursing women, patients with severe liver disease, severe aortic stenosis, biliary obstruction, renal dialysis, patients in shock, and patients with specific types of diabetes. Caution is needed when using this medication in hypotensive patients who are deficient in fluid or salt, as hypotension may occur; monitor their condition closely and take appropriate measures if hypotension occurs. Since blood vessels can dilate rapidly causing hypotension, particular caution should be exercised in patients with severe heart or vascular diseases. In patients with heart failure, this medication may affect heart function and should be used carefully; renal function changes should also be monitored in patients with reduced kidney function. Patients with impaired liver function should use this medication cautiously as its metabolism may be delayed. This medication may cause various side effects such as dizziness, headache, hypotension, orthostatic hypotension, edema, nausea, and vomiting, so any unusual symptoms should be discussed with a physician. During pregnancy, this medication should be avoided to prevent fetal damage, and patients planning to become pregnant should consider switching to safer alternative treatments. Women who are breastfeeding should stop nursing or discontinuing the medication as it may pass into breast milk and affect the infant. It is not recommended for patients under 18 years of age as the safety and efficacy in pediatric patients have not been established. Elderly patients may experience a different effect due to decreased kidney and liver function; therefore, treatment should start with a lower dose and their condition should be monitored closely. In cases of overdose, severe hypotension or heart problems may occur, and immediate medical attention should be sought. This medication should be stored in a tightly closed container, protected from direct sunlight and moisture, out of reach of children, and should not be transferred to another container. Moreover, this medication may interact with other antihypertensive drugs or specific medications, so patients must inform their doctor or pharmacist of any other drugs they are using.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to keep it at room temperature between 1 to 30 degrees Celsius to ensure its effectiveness.
Reddish-brown round film-coated tablet
28 tablets (14 tablets/AluAlu pack x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.